Eli Lilly and Company (NYSE: LLY) is one of the 10 Best AI Stocks to Buy According to Goldman Sachs. On September 18, Wells Fargo reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) stock, maintaining the price target at $1,100.

Eli Lilly said on Thursday the U.S. Food and Drug Administration has approved its treatment for a form of advanced breast cancer in adult patients who have received prior therapy. The therapy, Inluriyo,

HOUSTON — Eli Lilly and Co. (NYSE: LLY) has unveiled plans to build a new $6.5 billion manufacturing facility at Generation Park, a 4,000-acre master-planned development in northeast Houston that is owned by McCord Development.

Even though Eli Lilly and Company (NYSE:LLY)’s shares have lost 6.9% year-to-date, Cramer continues to be a believer in the stock.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was intended to prevent muscle loss in patients taking its blockbuster obesity treatment,

Eli Lilly (LLY) remains a strong growth company, driven by leadership in the booming GLP-1 and diabetes drug markets despite recent share price weakness. LLY's aggressive investments in manufacturing, superior clinical trial results, and AI-driven drug discovery reinforce its competitive edge and future revenue potential.

To avoid tariffs and boost production, Celltrion will pay $330 million to acquire a Branchburg manufacturing facility of Eli Lilly.

Eli Lilly will make its next-generation experimental weight-loss pill, orforglipron, at a new multi-billion-dollar manufacturing plant it plans to build in Texas, the company said on Tuesday. Lilly said it would invest $6.

Another multi-billion-dollar company is expanding operations in Texas after receiving millions of dollars through a new taxpayer funded grant that allows for a freeze on school district property tax increases for 10 years under a new law.

Eli Lilly will invest $6.5 billion to build a state-of-the-art biomanufacturing facility in Houston, creating 600 jobs and boosting production of advanced therapies.

Eli Lilly (NYSE: LLY) recently released top-line results from a head-to-head trial of its oral GLP-1 pill, orforglipron, compared to Novo Nordisk's (NYSE: NVO) oral version of Weg